Brainstorm Cell Therapeutics Inc. BCLI

BrainStorm Cell Therapeutics Inc. reported second quarter 2026 financial results and issued a corporate update. Financial results releases and corporate updates for a clinical-stage biotech typically affect near-term sentiment and valuation without altering long-term trajectory.

BrainStorm Cell Therapeutics Inc. (BCLI) reported its financial results for the second quarter of 2025, highlighting key metrics and developments within the company. The report includes updates on ongoing clinical trials and strategic initiatives aimed at advancing its product pipeline. Management provided insights into future plans and market positioning, emphasizing the company's commitment to innovation in cell therapy. The financial results and corporate updates indicate moderate influence on the company's performance and market sentiment.

BrainStorm Cell Therapeutics appoints former FDA Associate Commissioner Peter J. Pitts as Executive Chairman. Appointment adds FDA regulatory expertise that may aid future approvals without immediate major operational shifts.

BrainStorm Cell Therapeutics announced publication calling for updated FDA approaches to ALS, rare diseases and regenerative medicine. Calls for regulatory updates may moderately boost company positioning and sentiment around ALS and regenerative medicine programs.

BrainStorm Cell Therapeutics Inc. has partnered with Minaris to manufacture its investigational therapy, NurOwn, for an upcoming clinical trial. This collaboration aims to enhance the production process of NurOwn, which is being developed for the treatment of neurodegenerative diseases. The partnership is expected to streamline manufacturing and support the trial's objectives, potentially accelerating the development timeline for the therapy. The partnership with Minaris is a significant strategic move that could enhance manufacturing capabilities and support clinical trial success.

BrainStorm Cell Therapeutics appoints former FDA Associate Commissioner Peter J. Pitts to its Board of Directors. FDA regulatory expertise on board may aid approvals and strategy for cell therapies.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) has rescheduled its first quarter 2025 financial results release to post-market close on May 15, 2025, and will hold an investor conference call on May 19, 2025, at 8:30 a.m. Eastern Time. CEO Chaim Lebovits will provide a corporate update followed by a Q&A session with other executives. Investors can submit questions in advance and access the call via provided dial-in numbers or webcast. The company focuses on adult stem cell therapies for neurodegenerative diseases, with its lead therapy, NurOwn®, under regulatory review for ALS. BrainStorm has also made advancements in exosome technology and has received patent allowances to strengthen its intellectual property portfolio. The rescheduling of financial results and investor call indicates significant developments that could influence investor sentiment and market performance.

BrainStorm Cell Therapeutics reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates supply key performance metrics that influence near-term investor sentiment and valuation.

BrainStorm Cell Therapeutics Inc. (BCLI) reported its financial results for the first quarter of 2025, highlighting key metrics and developments within the company. The report includes updates on ongoing clinical trials and strategic initiatives aimed at advancing its product pipeline. Management provided insights into future plans and market positioning, emphasizing the company's commitment to innovation in cell therapy. The financial results and corporate updates indicate moderate influence on the company's performance and market sentiment.

BrainStorm Cell Therapeutics Inc. (BCLI) announced full year 2025 financial results and provided a corporate update. Annual financial results and corporate updates significantly impact investor sentiment, valuation, and strategic outlook for a clinical-stage biotech.

Brainstorm Cell Therapeutics Inc. reported its Q4 2024 earnings, highlighting key financial metrics and operational updates. The company discussed advancements in its product pipeline and ongoing clinical trials, emphasizing its commitment to innovation in neurodegenerative disease treatments. Management provided insights into future strategies and market positioning, aiming to enhance shareholder value. The earnings call revealed important updates on product development and financial performance that could moderately influence market perception and company trajectory.

BrainStorm Cell Therapeutics Inc. (BCLI) reported its full year 2024 financial results, highlighting key metrics and developments in its operations. The company provided an update on its ongoing projects and strategic initiatives aimed at advancing its therapeutic offerings. Financial performance indicators showed trends that may influence future growth and investor sentiment. The financial results and corporate updates indicate moderate influences on the company's performance and market positioning.

BrainStorm Cell Therapeutics Inc. (BCLI) reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its operations. The company provided updates on its ongoing clinical trials and strategic initiatives aimed at advancing its product pipeline. Management emphasized their commitment to innovation and addressing unmet medical needs in neurodegenerative diseases. The financial results reflected the company's current standing and future outlook. The financial results and updates on clinical trials indicate a moderately noticeable influence on the company's future performance and market positioning.

Brainstorm Cell Therapeutics Inc. is preparing to initiate the Phase 3b ENDURANCE trial of its investigational therapy, NurOwn®, for patients with amyotrophic lateral sclerosis (ALS). The trial aims to evaluate the efficacy and safety of NurOwn® in a larger patient population, building on previous positive results. The company is focused on advancing this critical study to potentially bring a new treatment option to ALS patients. The initiation of a Phase 3b trial for NurOwn® represents a significant strategic move that could greatly influence the company's future and market performance.

BrainStorm Cell Therapeutics Inc. (BCLI) is set to announce its second quarter financial results and provide a corporate update. The announcement is anticipated to include key insights into the company's financial performance and strategic direction. The upcoming financial results and corporate update may moderately influence investor sentiment and financial performance.

BrainStorm Cell Therapeutics Inc. (BCLI) announced its delisting from the Nasdaq Capital Market due to non-compliance with minimum shareholder equity requirements. Trading will be suspended on July 18, 2025, but the company has secured a transition to the OTCQB Venture Market, where it will continue trading under the same symbol. CEO Chaim Lebovits reassured stakeholders that this change does not affect the company's commitment to developing its NurOwn therapy for ALS patients. BrainStorm remains focused on its clinical programs and will continue to provide updates in compliance with SEC regulations. The delisting from Nasdaq and transition to OTCQB may moderately influence investor sentiment and market perception, but the company's core operations and commitment to its clinical programs remain intact.

BrainStorm Cell Therapeutics Inc. announced that the FDA is reviewing a Citizen Petition regarding NurOwn, its investigational therapy for ALS. The company supports this review, emphasizing the importance of scientific integrity and collaboration with the FDA. BrainStorm will continue with its Phase 3b ENDURANCE trial under an FDA Special Protocol Assessment to gather more data on NurOwn's efficacy and safety. Recent survival data from participants in an Expanded Access Program suggests promising outcomes, reinforcing the need for further exploration of NurOwn. The company remains committed to advancing access for ALS patients. The FDA's review of NurOwn data and the continuation of the Phase 3b trial could significantly impact BrainStorm's future and market performance.

A citizen's petition has been filed requesting the FDA to approve Brainstorm Cell Therapeutics Inc.'s NurOwn™ for the treatment of amyotrophic lateral sclerosis (ALS). The petition highlights the potential benefits of NurOwn™ and urges the FDA to expedite its review process. Supporters believe that the therapy could significantly improve patient outcomes, emphasizing the urgency given the lack of effective treatments for ALS. The petition aims to mobilize public and regulatory support for the approval of this innovative therapy. The petition could significantly influence regulatory approval and market perception of NurOwn™, impacting the company's future performance.

BrainStorm Cell Therapeutics Inc. announced that 90% of participants in its Expanded Access Program for NurOwn® treatment of ALS survived over five years from symptom onset. The analysis included 10 participants who had completed a Phase 3 trial, revealing a median survival of 6.8 years. This survival rate is significantly higher than the approximately 10% survival rate typically seen in ALS patients. The findings support the upcoming Phase 3b clinical trial of NurOwn, which aims to provide further evidence of its efficacy in treating ALS. The survival data suggests a significant potential for NurOwn to alter treatment outcomes in ALS, impacting future clinical trials and market perception.

BrainStorm Cell Therapeutics, Inc. (BCLI) received FDA clearance to initiate a Phase 3b trial of NurOwn® for ALS treatment. The trial, named ENDURANCE, will enroll approximately 200 patients and consists of a 24-week randomized, double-blind, placebo-controlled period followed by a 24-week open-label extension. Key changes from the previous Phase 3 trial include a focus on earlier-stage ALS patients and a different primary endpoint. The company has also secured manufacturing agreements with Pluri Inc. and Minaris Advanced Therapies to ensure adequate production of NurOwn. Additionally, new pharmacogenomic data presented at the ISCT 2025 Annual Meeting highlighted the impact of the UNC13A genotype on treatment outcomes. Financially, BrainStorm reported no revenues for Q1 2025 and is exploring funding options for the trial. FDA clearance for the Phase 3b trial and secured manufacturing capabilities are significant strategic moves that could alter the company's trajectory.

BrainStorm Cell Therapeutics Inc. has announced a strategic manufacturing partnership with Minaris to support the upcoming Phase 3b clinical trials of its NurOwn® treatment for amyotrophic lateral sclerosis (ALS). This collaboration aims to enhance the production capabilities necessary for the trial, which is a critical step in advancing the company's therapeutic development and addressing the needs of ALS patients. The partnership with Minaris is a significant strategic move that could enhance production capabilities and support the advancement of a key clinical trial.

The FDA has cleared BrainStorm Cell Therapeutics to begin a Phase IIIb trial of its NurOwn therapy for ALS, following a special protocol assessment agreement. The trial will enroll around 200 subjects and will include a 24-week double-blind, placebo-controlled phase, followed by an open-label extension. The primary goal is to assess changes in ALS Functional Rating Scale-Revised scores. Subjects will undergo bone marrow aspiration for stem cell isolation and cryopreservation, with the option to contribute to biomarker research. NurOwn aims to modulate neuroinflammation and promote neuroprotection in ALS patients. The therapy has received orphan drug designation from both the FDA and EMA. CEO Chaim Lebovits stated the company is preparing to enroll patients and secure funding for the trial. The FDA clearance for the Phase IIIb trial represents a significant step towards potential commercialization of a novel ALS treatment.

Brainstorm Cell Therapeutics Inc. (BCLI) reported highlights from its Q1 2025 earnings call, focusing on the pivotal Phase 3b clinical trial results for its lead product, which aims to treat neurodegenerative diseases. The company discussed advancements in its research, regulatory strategies, and financial performance, emphasizing its commitment to innovation and market expansion. Key metrics and future projections were also outlined, indicating a positive outlook for the company's growth trajectory. The pivotal Phase 3b trial results and strategic advancements are likely to significantly impact the company's future performance and investor sentiment.

Brainstorm Cell Therapeutics Inc. announced the clearance from the U.S. FDA to initiate its pivotal phase 3B trial for neuron, aimed at treating early-stage ALS patients. The trial, named Endurance, is designed to confirm the therapeutic benefits of neuron and has received alignment with the FDA on its endpoints. The company is actively negotiating clinical trial agreements with approximately 15 leading clinical centers in the U.S. and is preparing for manufacturing at the Tel Aviv Sosky Medical Center. The team is also exploring funding opportunities to support the trial's initiation and execution. Additionally, insights from recent presentations at the ALS summit highlighted the potential of neuron in ALS treatment and ongoing research into biomarkers and genetic factors influencing treatment response. The FDA clearance for the pivotal trial and the strategic partnerships being pursued are significant steps that could greatly influence the company's future and market performance.

BrainStorm Cell Therapeutics Inc. has received FDA clearance to initiate a Phase 3b clinical trial of its NurOwn® therapy for amyotrophic lateral sclerosis (ALS). The trial, which will enroll approximately 200 participants, follows a previously agreed-upon design with the FDA under a Special Protocol Assessment. The primary endpoint is the change in the ALS Functional Rating Scale-Revised after 24 weeks. CEO Chaim Lebovits emphasized the significance of this milestone for both the company and the ALS community, as they prepare to enroll patients and secure funding for the study. FDA clearance for a Phase 3b trial represents a significant step in the development of a potentially transformative therapy for ALS, impacting future market performance.

BrainStorm Cell Therapeutics Inc. (BCLI) will announce its first quarter results and provide a corporate update on May 15, 2025. This announcement is anticipated by stakeholders as it may offer insights into the company's financial performance and strategic direction. The upcoming announcement may influence financial performance and market sentiment but is not expected to fundamentally alter the company's trajectory.

BrainStorm Cell Therapeutics Inc. will present biomarker insights that support the mechanism of action and clinical impact of its NurOwn therapy at the 2025 ALS Drug Development Summit. This presentation aims to highlight the therapeutic potential of NurOwn in treating ALS, showcasing data that may enhance understanding of its efficacy and biological effects. The presentation of biomarker insights could significantly influence investor sentiment and the company's strategic positioning in the ALS treatment market.

BrainStorm Cell Therapeutics Inc. announced that new pharmacogenomic data on its NurOwn® therapy has been accepted for oral presentation at the ISCT 2025 Annual Meeting. The findings focus on the impact of the UNC13A genotype on ALS treatment response. CEO Chaim Lebovits emphasized the significance of these results in predicting treatment outcomes and the company's commitment to launching a Phase 3b trial for NurOwn. The trial aims to further validate the therapy's efficacy in early ALS, with positive communication ongoing with the FDA. The presentation will take place on May 8, 2025, in New Orleans. The acceptance of significant pharmacogenomic data for presentation and the upcoming Phase 3b trial are likely to enhance BrainStorm's market position and investor sentiment.

BrainStorm Cell Therapeutics Inc. has submitted an IND amendment to the FDA, which is a crucial step towards initiating a Phase 3b clinical trial for its NurOwn® treatment in patients with amyotrophic lateral sclerosis (ALS). This amendment aims to address feedback from the FDA and is expected to facilitate the advancement of the trial, potentially leading to new treatment options for ALS patients. The IND amendment is a significant regulatory step that could greatly impact the company's future product development and market positioning in the ALS treatment landscape.

Brainstorm Cell Therapeutics Inc. (BCLI) reported its Q4 2024 earnings, highlighting key financial metrics and strategic initiatives. The company is navigating challenges in the biotech sector while focusing on advancing its product pipeline. Management discussed ongoing clinical trials and potential market opportunities, emphasizing the importance of regulatory developments. Investors were briefed on cash flow management and future funding strategies to support growth. Ongoing clinical trials and financial management may moderately influence the company's performance and market sentiment.